2010 Gross Profit up $2 Million; Net Loss Decreased $2.8 Million
Conference call at 8:30am ET to discuss results
WIXOM, Mich., March 3, 2011 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency anemia, reported today fourth quarter and full-year 2010 results:Fourth Quarter Financial Highlights
- Sales were $14.3 million, a 3% decrease compared to the fourth quarter of 2009.
- Gross profit margin increased to 16.6%, compared to gross profit margin of 16.4% in the fourth quarter of 2009.
- R&D expense was $1.7 million, compared to $1.1 million in the fourth quarter 2009.
- Net loss of ($1.7) million, compared to a net loss of ($0.5) million in the fourth quarter 2009.
- Sales were $59.6 million, an increase of $4.8 million or 8.8%, compared to 2009.
- Gross profit margins were 16.6%, an increase of 2.2 percentage points compared to gross profit margin of 14.4% in 2009.
- Gross profit increased $2 million or 25% to $9.9 million compared to $7.9 million in 2009.
- R&D expense was $3.4 million compared to $6.5 million in 2009.
- Net loss of ($2.7) million, compared to a net loss of ($5.5) million in 2009.
- Net loss includes non-cash equity compensation charges of $ 4.0 million.
- Year-end cash position of $24.2 million.
- Commenced patient screening for Phase III CRUISE clinical trials.
- Submitted Phase III study protocol to FDA and completed site feasibility study.
- Confirmed acceptable Phase III primary efficacy endpoint with FDA.
- Commenced patient enrollment for ESA-sparing PRIME study.
- Presented new ESA sparing and iron repletion data at ASN 2010.
- Received U.S. patent for proprietary SFP formula extending intellectual property protection to 2029.
- Appointed Dr. Ajay Singh and Dr. Ian Macdougall to Scientific Advisory Board.
- Hired VP of Business Development/Investor Relations.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV